Hepion Pharmaceuticals Inc Stock

$0.07

6.40% yesterday

Nasdaq, Jun 27, 09:07 pm CET

ISIN

US4268971045

Symbol

HEPA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Hepion Pharmaceuticals Inc Stock price

$0.07

-2,839.93 100.00% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.00 6.40%

ISIN

US4268971045

Symbol

HEPA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$770.0k

Enterprise Value

$3.3m

Net debt

$2.5m

Cash

$410.0k

Shares outstanding

140.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-115.47%

Return on Equity

708.01%

ROCE

1,264.48%

ROIC

Debt/Equity

-1.56

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-19.3m | -

EBIT

$-19.3m

Net Income

$-13.2m | $-740.0k

Free Cash Flow

$-18.2m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

57.25% | -

EBIT

57.25%

Net Income

73.04% | 94.39%

Free Cash Flow

55.45%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-94.67

FCF per Share

$-130.12

Short interest

4.10%

Employees

22.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Hepion Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Hepion Pharmaceuticals Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Hepion Pharmaceuticals Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Hepion Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	7.50 7.50	22% 22% -
- Research and Development Expense	12 12	67% 67% -
EBITDA	-19 -19	57% 57% -
- Depreciation and Amortization	0.03 0.03	57% 57% -
EBIT (Operating Income) EBIT	-19 -19	57% 57% -
Net Profit	-13 -13	73% 73% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Hepion Pharmaceuticals Inc Stock News

Neutral

GlobeNewsWire

●

3 days ago

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H.

Neutral

GlobeNewsWire

●

about 2 months ago

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multi...

Neutral

GlobeNewsWire

●

about 2 months ago

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a binding letter of intent (“LOI”) with New Day Diagnostics LLC to in...

More Hepion Pharmaceuticals Inc News

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Head office	United States
CEO	John Brancaccio
Employees	22
Founded	2013
Website	hepionpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now